Pharmaceutical company in the
Canton of Geneva

Telix Pharmaceuticals (Switzerland) Sàrl

Since 1999 · 21–50 empl.

Telix Pharmaceuticals (Switzerland) Sàrl operates in the field of radiopharmaceuticals for cancer diagnosis and treatment. The company develops imaging agents and targeted therapies that use radioactive substances to detect or treat cancer cells.

Botavie SA

Since 2000 · 1–10 empl.

Botavie SA offers plant-based dietary supplements and health products formulated according to the Unani tradition and markets them online under the BOTAVIE and IRELIA brands.

Addex Pharma SA

Since 2002 · 1–10 empl.

Addex Pharma SA is a clinical-stage biopharmaceutical company developing novel small-molecule allosteric modulators for neurological disorders. Its development programs include drug candidates for recovery after stroke or traumatic brain injury, as well as for substance use disorders and chronic cough.

Desaturase SA

Since 2003 · 1–10 empl.

Desaturase SA sells dietary supplements under the Delta 6 Desaturase product range. The products are offered with specific formulations and selected ingredients.

Epithelix Sàrl

Since 2006 · 11–20 empl.

Epithelix Sàrl develops and produces in vitro models of human respiratory tissues, as well as cells, cell and tissue extracts, and culture media. The biotechnology company also provides testing services to assess drugs and chemical compounds, including studies of respiratory toxicity, infections, and inflammation.

Laboratoires Elveapharma Sàrl

Since 2008 · 11–20 empl.

Laboratoires Elveapharma Sàrl develops and markets natural food supplements made from nutrients and natural substances. Its products are sold through pharmacies and drugstores in Switzerland and an online shop.

Bionoltra SA

Since 2008 · 11–20 empl.

Bionoltra SA develops and manufactures medical products for orthopedics and urology. Its range includes injectable products for joint conditions associated with osteoarthritis and a product for the endoscopic treatment of vesicoureteral reflux.

SOLID Drug Development SA

Since 2010 · 1–10 empl.

SOLID Drug Development SA is a strategic and operational consultancy for the development of biotechnology and pharmaceutical products. Its services cover CMC, non-clinical and clinical development, regulatory and strategic matters, and technology transfer.

EHC (EUROPEAN HEALTH CORPORATION) SA

Since 2010 · 1–10 empl.

EHC (EUROPEAN HEALTH CORPORATION) SA operates in consumer healthcare and develops products and solutions for health and self-care. Its activities include acquiring, licensing, distributing and promoting brands, with products such as over-the-counter medicines, medical devices and food supplements.

VASPERIS SA

Since 2010 · 11–20 empl.

CROSS PHARM SA

Since 2013 · 1–10 empl.

CROSS PHARM SA is a pharmaceutical company involved in the development, manufacture and marketing of medicines. Its portfolio includes antibiotics, antiemetics, muscle relaxants, and vitamin and mineral products; the company also carries out pharmacovigilance.

APTISSEN SA

Since 2013 · 51–100 empl.

APTISSEN SA offers products for musculoskeletal conditions. Its range includes injectable hyaluronic acid and sorbitol gels for viscosupplementation, as well as a drinkable food supplement for joints.

ReMedys Foundation

Since 2013 · 11–20 empl.

ReMedys Foundation is a not-for-profit foundation that supports translational research and the development of new therapies for patients with severe diseases lacking effective treatments. It brings together academic researchers and industry experts and runs programs focused on healthspan and ALS.

Ageronix SA

Since 2013 · 1–10 empl.

Ageronix SA develops Alpha-1 Antitrypsin-based therapies for neurological disorders. Its lead development program targets Charcot-Marie-Tooth disease, with additional programs focused on Alzheimer's disease and other neurodegenerative conditions.

Bailleul (Suisse) SA

Since 2014 · 11–20 empl.

Bailleul (Suisse) SA is a pharmaceutical company that develops and markets medicines, food supplements and dermocosmetic products. Its areas of focus include dermatological conditions such as hair loss, acne and fungal skin infections, as well as women's health.

ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA

Since 2014 · 11–20 empl.

The core activity of Advanced Accelerator Applications (AAA) is the development and delivery of products and services in the field of nuclear medicine, particularly in the areas of radioligand therapy (RLT) and molecular imaging with positron emission tomography (PET).

Santen SA

Since 2014 · 101–500 empl.

Santen SA is a pharmaceutical company focused on ophthalmology. It develops and markets medicines and medical devices, including products for glaucoma and dry eye disease, and also operates in the fields of eye surgery and vision correction.

DermAbiotech Sàrl

Since 2014 · 1–10 empl.

SYRHATECH SA

Since 2015 · 11–20 empl.

SYRHATECH SA develops and manufactures injectable medical devices, mainly based on hyaluronic acid and other biopolymers. Its contract development and manufacturing services include research and development, formulation, production and analytical testing for medical applications.

CELL RECEPTOR SA

Since 2015 · 1–10 empl.

CELL RECEPTOR SA develops a cell biology-based therapeutic approach for cancer and autoimmune diseases. The company researches how interactions between tumour cells and blood platelets affect cell growth and is working towards clinical application of its approach.

Kyowa Kirin Sàrl

Since 2016 · 21–50 empl.

The core activity of Krystal Biotech, Inc. is the development and manufacture of pharmaceuticals, particularly biopharmaceuticals. The company focuses on the research and development of new therapeutics based on genetic and biotechnological methods. The company's products aim to treat various diseases and conditions, including rare genetic disorders.

Atopia Therapeutics SA

Since 2016 · 1–10 empl.

Atopia Therapeutics SA develops drug candidates for asthma and other allergic diseases. Its candidate ATP-R13 is a recombinant immunomodulatory protein being developed as an oral therapy.

STALICLA SA

Since 2017 · 11–20 empl.

STALICLA SA develops personalized treatment approaches for neurological and neuropsychiatric disorders, particularly autism spectrum disorders. Its DEPI platform uses multiomics, patient data and artificial intelligence to match patient groups with suitable drug treatments.

iOnctura SA

Since 2017 · 21–50 empl.

iOnctura SA is a biotechnology company developing small-molecule cancer therapies. Its drug pipeline includes candidates targeting PI3Kδ, autotaxin and the TGF-β pathway for hard-to-treat cancers.

Gliapharm SA

Since 2017 · 11–20 empl.

Gliapharm SA researches and develops drug candidates for neurological disorders by targeting metabolic pathways in astrocytes, a type of glial cell. Its drug discovery platform identifies and characterizes molecular targets and potential medicines, and is also used in research with academic and industry partners.

MPC Therapeutics SA

Since 2018 · 11–20 empl.

MPC Therapeutics SA develops small molecules and reagents for metabolic modulation of cell therapies. Its products support the manufacture and function of CAR-T cells, including by promoting their expansion, metabolic fitness and persistence.

Relief Therapeutics International SA

Since 2018 · 21–50 empl.

Relief Therapeutics International SA develops therapeutic solutions in neurotherapy and digital rehabilitation. The company offers combined approaches that use software, devices, data, and behavior-based applications for therapy and monitoring.

Pharmex SA

Since 2018 · 51–100 empl.

The company's core activity encompasses the development, manufacture, and marketing of products and services in the following areas: * Pharmaceuticals: development and manufacture of medicines and medical devices, including generics and OTC products * Cosmetics: development and manufacture of premium cosmetic products for the general consumer and pediatric care * Dietary supplements: development and manufacture of dietary supplements (Food Supplements) * Services: provision of Contract Manufacturing Organization (CMO) services for pharmaceuticals, cosmetics, and biocides, as well as research and development (R&D) services for these areas. Thus, the company offers a wide range of products and services focusing on the areas of health, beauty, and wellness.

Vaccine Formulation Institute SA

Since 2020 · 21–50 empl.

Vaccine Formulation Institute SA develops vaccine adjuvants and formulations for research and development. It optimises and characterises formulations, supports preclinical and clinical development and technology transfer for manufacturing and quality control, and provides training.

argenx Switzerland SA

Since 2020 · 11–20 empl.

argenx Switzerland SA operates in immunology and develops medicines for immune-mediated diseases. Its activities include research, development of a product pipeline, clinical trials, and collaboration with scientists and researchers.

CDC LAB SA

Since 2021 · 11–20 empl.

CDC LAB SA produces and distributes medical cannabis flowers and plant-based pharmaceutical active ingredients and raw materials. Its services include laboratory analysis according to pharmacopoeias, advice on production and analysis, and contract manufacturing of compounded preparations for Swiss pharmacies.

SUBSTIPHARM BIOLOGICS SA

Since 2022 · 11–20 empl.

SUBSTIPHARM BIOLOGICS SA acquires and commercializes vaccines. Its activities focus on expanding regional access to clinically proven vaccines, including vaccines against Japanese encephalitis and Enterovirus 71.

Release Therapeutics SA

Since 2005 · 1–10 empl.

The core activity of Relief Therapeutics is the development and marketing of new, patented therapeutics for rare and ultra-rare diseases, particularly for patients with severe illnesses for which there are currently no or only limited treatment options. The company focuses on developing medications for specific diseases such as Epidermolysis Bullosa, Phenylketonuria and other rare conditions.

T.R.B. INTERNATIONAL SA

Since 2009 · 21–50 empl.

T.R.B. INTERNATIONAL SA manufactures and distributes pharmaceutical and biotechnological products, with a focus on ophthalmology and rheumatology. Its portfolio includes hyaluronic acid products for dry eye, joint and tendon conditions, as well as arthroscopy.

Advanced Biotech Laboratories Switzerland SA

Since 2010 · 21–50 empl.

The core activity of Advanced Biotech Laboratories Switzerland SA is the selection and promotion of high-quality anti-aging products and luxury health services, particularly in the field of cell therapy and stem cell research. The company collaborates with various clinics and laboratories to offer innovative products and services in the field of health and beauty.

AMAL THERAPEUTICS SA

Since 2012 · 21–50 empl.·5.0(2)

The core activity of AMAL Therapeutics is the development of therapeutic cancer vaccines, particularly using its proprietary KISIMA immunization technology, which aims to stimulate the patient's immune response against cancer cells.

Atheris SA

Since 2012 · 11–20 empl.

Geneva Biotech Center (GBC) SA

Since 2013 · 11–20 empl.

The core activity of Atopia Tx is the development of innovative therapies for asthma and allergic diseases, in particular the development of a first disease-modifying therapeutic for asthma and allergies based on a molecule from Helicobacter pylori.